University of Ottawa, Ottawa, ON, Canada
Victor Lo , Ranjeeta Mallick , Rachel Anne Goodwin , Joanna Gotfrit
Background: Locally advanced rectal cancer patients require multidisciplinary care for treatment planning. We sought to determine whether the order of surgical and radiation oncology consultation in relation to medical oncology consultation affects the time from cancer diagnosis to treatment initiation and the requirement for additional pre-treatment visits with medical oncology. Methods: We conducted a retrospective chart review of adult patients referred to The Ottawa Hospital with locally advanced rectal adenocarcinoma, seen in consultation by a surgical, radiation, and medical oncologist between January 2018 and December 2022. Results: Of 195 patients, the median time from diagnosis to treatment was 55 days (IQR: 45-68). Both surgical and radiation oncology consultation preceded medical oncology consultation in a minority of patients (72; 37%), and 48 (25%) patients required multidisciplinary cancer conference (MCC) discussion. However, the time from cancer diagnosis to treatment initiation was not significantly different between patients who were and were not seen by the surgeon and radiation oncologist prior to the medical oncologist (56 vs. 55 days respectively), nor if MCC discussions were or were not required (55 vs. 55 days). However, almost half of all patients (93; 48%) required an additional pre-treatment visit with their medical oncologist, and patients who saw both surgical and radiation oncology prior were significantly less likely to require additional pre-treatment visits with medical oncology (25% vs. 61%; p<0.0001). Conclusions: The time from cancer diagnosis to treatment initiation was not significantly impacted by the order of specialist consultations with the multidisciplinary team, nor if patients required MCC discussion or additional pre-treatment visits with medical oncology. However additional pre-treatment visits with medical oncology were significantly more likely to occur when patients were seen by medical oncology prior to surgical and/or radiation oncology, representing a logistical and financial inefficiency in the system, and a potential area for process improvement.
No Additional Visits with Med Onc | One or More Additional Visits with Med Onc | Proportion of Patients Who Required Additional Visit(s) with Med Onc | p | |
---|---|---|---|---|
Seen surg onc prior to med onc | 74 (38%) | 42 (22%) | 42/116 (36%) | <0.0001 |
Did not see surg onc prior to med onc | 28 (14%) | 51 (26%) | 51/79 (65%) | |
Seen rad onc prior to med onc | 77 (34%) | 44 (23%) | 44/121 (26%) | <0.0001 |
Did not see rad onc prior to med onc | 25 (13%) | 49 (25%) | 49/74 (66%) | |
Seen both surg&rad onc prior to med onc | 54 (28%) | 18 (9%) | 18/72 (25%) | <0.0001 |
Did not see both surg&rad onc prior to med onc | 48 (25%) | 75 (38%) | 75/123 (61%) |
surg onc surgical oncologist; rad onc radiation oncologist; med onc medical oncologist.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Katie Nadine Lee
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Felipe Fernando Quezada
2021 ASCO Annual Meeting
First Author: Kathryn Ries Tringale
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Raunaq Puri